Assets Held for Sale	6 Months Ended
Dec. 31, 2021
Assets Held for Sale
Assets held for Sale	Note 20. Assets Held for Sale Cody API Real Estate In Fiscal 2020, the Company ceased operations at Cody Labs, leased a portion of the real estate to a third party and intends to sell the remaining real estate. In November 2021, the Company entered into an agreement for the sale of real estate associated with the Cody API business. The Company adjusted the carrying value to fair value based on the signed agreement and estimated proceeds of the sale, which resulted in a $0.5 million impairment charge. As of December 31, 2021, the remaining real estate associated with the Cody API business, totaling $2.2 million, was recorded in the assets held for sale caption in the Consolidated Balance Sheets. The financial results of the Cody API business for the three and six months ended December 31, 2021 and 2020 were not material to the Company’s Consolidated Statements of Operations. Silarx Pharmaceuticals, Inc. Facility in Carmel, New York In November 2021, the Company announced the 2021 Restructuring Plan, which includes consolidating its manufacturing footprint by transferring certain liquid drug production from its Silarx Pharmaceuticals, Inc. (“Silarx”) facility in Carmel, New York to the Company’s main plant in Seymour, Indiana. Following the transition, which is expected to take 12 to 18 months, the Company intends to shut down operations at the Silarx facility. The Company is also currently pursuing the sale of the facility, which is anticipated to occur within one year and may result in accelerated timing for the shutdown of operations at Silarx. As such, the facility and certain equipment identified for sale are considered held for sale as of December 31, 2021. The Company subsequently performed a fair value analysis which resulted in an $8.4 million impairment charge of the Silarx facility and certain equipment at the facility in the second quarter of Fiscal 2022. As of December 31, 2021, the facility and equipment identified for sale, totaling $10.5 million, was recorded in the assets held for sale caption in the Consolidated Balance Sheet.

Assets Held for Sale

6 Months Ended

Dec. 31, 2021

Note 20. Assets Held for Sale

Cody API Real Estate

In Fiscal 2020, the Company ceased operations at Cody Labs, leased a portion of the real estate to a third party and intends to sell the remaining real estate. In November 2021, the Company entered into an agreement for the sale of real estate associated with the Cody API business. The Company adjusted the carrying value to fair value based on the signed agreement and estimated proceeds of the sale, which resulted in a $0.5 million impairment charge. As of December 31, 2021, the remaining real estate associated with the Cody API business, totaling $2.2 million, was recorded in the assets held for sale caption in the Consolidated Balance Sheets. The financial results of the Cody API business for the three and six months ended December 31, 2021 and 2020 were not material to the Company’s Consolidated Statements of Operations.

Silarx Pharmaceuticals, Inc. Facility in Carmel, New York

In November 2021, the Company announced the 2021 Restructuring Plan, which includes consolidating its manufacturing footprint by transferring certain liquid drug production from its Silarx Pharmaceuticals, Inc. (“Silarx”) facility in Carmel, New York to the Company’s main plant in Seymour, Indiana. Following the transition, which is expected to take 12 to 18 months, the Company intends to shut down operations at the Silarx facility. The Company is also currently pursuing the sale of the facility, which is anticipated to occur within one year and may result in accelerated timing for the shutdown of operations at Silarx. As such, the facility and certain equipment identified for sale are considered held for sale as of December 31, 2021. The Company subsequently performed a fair value analysis which resulted in an $8.4 million impairment charge of the Silarx facility and certain equipment at the facility in the second quarter of Fiscal 2022. As of December 31, 2021, the facility and equipment identified for sale, totaling $10.5 million, was recorded in the assets held for sale caption in the Consolidated Balance Sheet.